Summary: Remarkable progress has been made in inhalation techniques over the past 20 years, resulting in better lung deposition of drugs. Patients need to be educated in inhalation techniques and this is a challenging task during the pandemic due to limited face-to-face contact with medical staff. The latest publications of GINA and GOLD strategies have recommended maintaining inhaled drugs in asthma and COPD; nebulization should be avoided, as the aerosolization of respiratory particles could be more dangerous in the context of possible virus transmission. The preferable inhalation technique is MDI with aerochamber, in both children and adults. The Modulite technique of inhalation has been patented and represents the MDI type of device ‒ this technique allows to achieve smaller respiratory particles (MMAD < 2 µm). This technology allows the development of ozone-friendly inhaled drugs that replace the same doses of chlorofluorocarbon (CFC)-formulated products and enables the attainment of new formulations with extra-fine particles and improved lung deposition. Clinical pharmacology as well as clinical studies against comparators have demonstrated that formoterol Modulite and the existing dry powder inhaler and CFC formoterol formulations have a similar pharmacokinetic profile, are clinically equivalent in their bronchodilating effects, and exhibit similar potential for systemic side effects. Therefore, the Modulite formoterol hydrofluoroalkane-based formulation in extra-fine particles is a valuable therapeutic option for both patients and physicians in the management of asthma and chronic obstructive pulmonary disease.